Publications by authors named "I Haraldsson"
Microvesicles in plasma reflect coronary flow reserve in patients with cardiovascular disease.
Am J Physiol Heart Circ Physiol
May 2021
High levels of microvesicles (MVs), a type of extracellular vesicles, are detected in several pathological conditions. We investigated the connection between coronary flow reserve (CFR), a prognostic clinical parameter that reflects blood flow in the heart, with levels of MVs and their cargo, from plasma of patients with cardiovascular disease. The PROFLOW study consists of 220 patients with prior myocardial infarction and measured CFR with transthoracic echocardiography.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the outcomes of patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention using either radial or femoral artery access.
- Data from the SWEDEHEART registry indicated that radial access was linked to a significantly lower risk of 30-day mortality, in-hospital bleeding, and cardiogenic shock compared to femoral access.
- These results support the preference for radial access in these procedures and align with findings from recent randomized trials, reinforcing the benefits of this approach.
Article Synopsis
- Pretreatment with P2Y12 receptor antagonists for patients with NSTE-ACS undergoing PCI is common but lacks strong evidence for its benefits.
- A study using data from nearly 65,000 patients in Sweden found no significant association between pretreatment and improved survival rates, stent thrombosis, or in-hospital bleeding.
- Despite high rates of pretreatment (over 92%), outcomes like 30-day mortality and stent thrombosis were not significantly better in those pretreated compared to those without pretreatment.
Article Synopsis
- Ticagrelor is a medication that reduces heart-related issues in patients with acute coronary syndromes, but its effectiveness compared to clopidogrel in real-world settings is unclear.
- A study using data from a Swedish registry evaluated 15,097 patients who received either ticagrelor or clopidogrel during percutaneous coronary interventions (PCI) over a 10-year period.
- The results showed that ticagrelor did not significantly lower the risk of major complications like death or stent thrombosis compared to clopidogrel, and it was associated with a higher risk of in-hospital bleeding.
Background: Survivors of myocardial infarction (MI) are at high risk of new major adverse cardiovascular events (MACE). Coronary flow reserve (CFR) is a strong and independent predictor of MACE. Understanding the prevalence of impaired CFR in this patient group and identifying risk markers for impaired CFR are important steps in the development of personalized and targeted treatment for high-risk individuals with prior MI.
View Article and Find Full Text PDF